2.16.840.1.113883.10.22.4.3 - Revision history

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2024-08-05T05:11:49Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2024-06-13T05:11:45Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2024-04-03T05:11:54Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2022-11-14T07:11:43Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-09-30T05:13:00Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-09-07T05:13:12Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-09-03T05:13:20Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-08-05T05:14:20Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-08-03T05:14:00Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

ADbot: Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

2021-01-05T16:46:43Z

Automatic ADBot page (a88dfd3ec0893a46f167b13b3c63ebc18cfd5540)

@@ Line 20: / Line 20: @@
 ==List of all versions of this template==
 *[[2.16.840.1.113883.10.22.4.3/static-2021-08-02T165227|2021-08-02 16:52:27 (Under develeopment)]]
 *[[2.16.840.1.113883.10.22.4.3/static-2016-11-10T000000|2016-11-10 (Under pre-publication review)]]
-<!--c201e9dae9a1be24f35a9cb172c1f82965a25dbd-->
+<!--5f5f50fd8eced477b697f97c594748e37ebb10e1-->

@@ Line 5: / Line 5: @@
 =Template ''IPSMedMaterial''=
-<p>This entry provides details about the medicinal product.Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.This shortage will
+<p>
-                    be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in
+                This entry provides details about the medicinal product.
-                    the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide all the available information that could be helpful for the identification of medicationsJurisdictions could
+                Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.
-                    specialize this template making some ofthese attributes required.It is also recognized that in many contexts structured information about the product, might not be available, and only textual information for describing products (e.g. the product scientific name "amoxicillin 400mg/5mL suspension”) or some of their attributes (e.g. textual strength "875 mg + 125 mg" ;
+                This shortage will be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).
-                    "amoxycillin and clavulanic acid") could be used. This template attempts to provide a solution that takes in account this current complexity being also ready for including the future IDMP-based solution as soon as they will become available for concrete use.Since the CDA R2.0 model support only a very limited set of information about the products,
+                Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide
-                    extensions based on the R_ProductList (Common Product Model) CMET have been used for conveying such information, aiming to align this solution with that that will be likely used for the IDMP implementation Guide.</p>
+                    all the available information that could be helpful for the identification of medications
 ==Actual version==
 {{:{{BASEPAGENAME}}/dynamic}}
@@ Line 17: / Line 22: @@
 *[[2.16.840.1.113883.10.22.4.3/static-2021-08-02T165227|2021-08-02 16:52:27 (Under develeopment)]]
 *[[2.16.840.1.113883.10.22.4.3/static-2016-11-10T000000|2016-11-10 (Under pre-publication review)]]
-<!--0bb1cee7bf54d8e414d4a92f5966077cd8a4ee6b-->
+<!--c201e9dae9a1be24f35a9cb172c1f82965a25dbd-->

@@ Line 5: / Line 5: @@
 =Template ''IPSMedMaterial''=
-<p>This entry provides details about the medicinal product.Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.This shortage will be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide all the available information that could be helpful for the identification of medicationsJurisdictions could specialize this template making some ofthese attributes required.It is also recognized that in many contexts structured information about the product, might not be available, and only textual information for describing products (e.g. the product scientific name "amoxicillin 400mg/5mL suspension”) or some of their attributes (e.g. textual strength "875 mg + 125 mg" ; "amoxycillin and clavulanic acid") could be used. This template attempts to provide a solution that takes in account this current complexity being also ready for including the future IDMP-based solution as soon as they will become available for concrete use.Since the CDA R2.0 model support only a very limited set of information about the products, extensions based on the R_ProductList (Common Product Model) CMET have been used for conveying such information, aiming to align this solution with that that will be likely used for the IDMP implementation Guide.</p>
+<p>This entry provides details about the medicinal product.Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.This shortage will
 ==Actual version==
 {{:{{BASEPAGENAME}}/dynamic}}
@@ Line 12: / Line 17: @@
 *[[2.16.840.1.113883.10.22.4.3/static-2021-08-02T165227|2021-08-02 16:52:27 (Under develeopment)]]
 *[[2.16.840.1.113883.10.22.4.3/static-2016-11-10T000000|2016-11-10 (Under pre-publication review)]]
-<!--51693573eab0d97a85daef8ab30f16364451529b-->
+<!--0bb1cee7bf54d8e414d4a92f5966077cd8a4ee6b-->

@@ Line 5: / Line 5: @@
 =Template ''IPSMedMaterial''=
-<p>
+<p>This entry provides details about the medicinal product.Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.This shortage will be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide all the available information that could be helpful for the identification of medicationsJurisdictions could specialize this template making some ofthese attributes required.It is also recognized that in many contexts structured information about the product, might not be available, and only textual information for describing products (e.g. the product scientific name "amoxicillin 400mg/5mL suspension”) or some of their attributes (e.g. textual strength "875 mg + 125 mg" ; "amoxycillin and clavulanic acid") could be used. This template attempts to provide a solution that takes in account this current complexity being also ready for including the future IDMP-based solution as soon as they will become available for concrete use.Since the CDA R2.0 model support only a very limited set of information about the products, extensions based on the R_ProductList (Common Product Model) CMET have been used for conveying such information, aiming to align this solution with that that will be likely used for the IDMP implementation Guide.</p>
 ==Actual version==
 {{:{{BASEPAGENAME}}/dynamic}}
@@ Line 21: / Line 12: @@
 *[[2.16.840.1.113883.10.22.4.3/static-2021-08-02T165227|2021-08-02 16:52:27 (Under develeopment)]]
 *[[2.16.840.1.113883.10.22.4.3/static-2016-11-10T000000|2016-11-10 (Under pre-publication review)]]
-<!--dfe9f3b199103b1018883d6137a9eb81cc77c840-->
+<!--51693573eab0d97a85daef8ab30f16364451529b-->

@@ Line 5: / Line 5: @@
 =Template ''IPSMedMaterial''=
-<p>This entry provides details about the medicinal product.
+<p>
-Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.
+      This entry provides details about the medicinal product.
-This shortage will be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).
+      Due to the current absence of global product identifiers the product is described through a set of identification and descriptive attributes (e.g. active substances, strength, unit of presentation,...)  that may be used to integrate jurisdictional product codes.
-Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide all the available information that could be helpful for the identification of medications
+      This shortage will be likely overcome when the ISO IDMP identifiers will be available for concrete usage in the next years, as well as the globally used value sets for products attributes agreed by the ISO IDMP implemention guides. (e.g. GInAs for substances).
-Jurisdictions could specialize this template making some ofthese attributes required.
+      Even though there is a quite common consensus about the attributes that should be provided in order to describe a medicine in the context of the international patient summary (e.g. the list of active substances, the strength(s); the administrable pharmaceutical forms;..), this template doesn't require any of them, recommending, above all for cross-borders services, to provide all the available information that could be helpful for the identification of medications
-It is also recognized that in many contexts structured information about the product, might not be available, and only textual information for describing products (e.g. the product scientific name "amoxicillin 400mg/5mL suspension”) or some of their attributes (e.g. textual strength "875 mg + 125 mg" ; "amoxycillin and clavulanic acid") could be used.
+      Jurisdictions could specialize this template making some ofthese attributes required.
-This template attempts to provide a solution that takes in account this current complexity being also ready for including the future IDMP-based solution as soon as they will become available for concrete use.
+      It is also recognized that in many contexts structured information about the product, might not be available, and only textual information for describing products (e.g. the product scientific name "amoxicillin 400mg/5mL suspension”) or some of their attributes (e.g. textual strength "875 mg + 125 mg" ; "amoxycillin and clavulanic acid") could be used.
-Since the CDA R2.0 model support only a very limited set of information about the products, extensions based on the R_ProductList (Common Product Model) CMET have been used for conveying such information, aiming to align this solution with that that will be likely used for the IDMP implementation Guide.</p>
+      This template attempts to provide a solution that takes in account this current complexity being also ready for including the future IDMP-based solution as soon as they will become available for concrete use.
 ==Actual version==
 {{:{{BASEPAGENAME}}/dynamic}}
@@ Line 19: / Line 21: @@
 *[[2.16.840.1.113883.10.22.4.3/static-2021-08-02T165227|2021-08-02 16:52:27 (Under develeopment)]]
 *[[2.16.840.1.113883.10.22.4.3/static-2016-11-10T000000|2016-11-10 (Under pre-publication review)]]
-<!--d3d4c4fee489de3bf0e1a0778882e05a14b573b5-->
+<!--dfe9f3b199103b1018883d6137a9eb81cc77c840-->